Israel Englander is a billionaire hedge fund manager and serves as the CEO of Millennium Management. During the second quarter, Millennium initiated a new position that I found to be quite curious.
Summit Therapeutics SMMT reported third-quarter 2024 loss per share of 8 cents, wider than the Zacks Consensus Estimate of a loss of 7 cents. In the year-ago period, the company posted a loss of 3 ...
Zacks.com on MSN20d
Summit Therapeutics Stock: Sell or Hold Before Q3 Earnings?Last month, Summit reported additional results from the HARMONi-2 study, which evaluated ivonescimab against Merck’s ... of ...
Merck (MRK) will be in focus as company beats revenue forecasts despite in line earnings amid strong Keytruda sales in Q3 ...
The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...
Merck & Co reported stronger-than-expected quarterly earnings thanks to rising Keytruda sales. However, Gardasil's weak ...
Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.
Merck reported third-quarter revenue and adjusted earnings that topped expectations. The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback